Compare BENF & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BENF | NEPH |
|---|---|---|
| Founded | 2003 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.3M | 60.0M |
| IPO Year | N/A | 2004 |
| Metric | BENF | NEPH |
|---|---|---|
| Price | $5.39 | $5.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 304.7K | 39.9K |
| Earning Date | 02-12-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | ★ $17,930,000.00 |
| Revenue This Year | N/A | $33.32 |
| Revenue Next Year | N/A | $12.27 |
| P/E Ratio | ★ N/A | $37.16 |
| Revenue Growth | N/A | ★ 32.36 |
| 52 Week Low | $1.75 | $1.39 |
| 52 Week High | $12.48 | $6.42 |
| Indicator | BENF | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 54.18 | 50.82 |
| Support Level | $5.01 | $4.74 |
| Resistance Level | $7.68 | $5.46 |
| Average True Range (ATR) | 1.46 | 0.32 |
| MACD | -0.29 | 0.03 |
| Stochastic Oscillator | 18.23 | 51.86 |
Beneficient is a technology-enabled financial services holding company that (together with its subsidiaries) provides simple, rapid, and cost-effective liquidity solutions to participants in the alternative asset industry through its end-to-end online platform, AltAccess. BCG's products and services are designed to meet the unmet needs of mid-to-high net-worth individual investors, small-to-midsize institutional investors, family offices, and fund general partners. Its bespoke liquidity solutions for otherwise illiquid alternative asset investments are delivered through proprietary technology and a financing and trust structure. It has three reportable segments consisting of Ben Liquidity, Ben Custody and Customer ExAlt Trusts.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.